Alumis (ALMS) Receivables (2025)

Alumis (ALMS) posted quarterly Receivables of $1.4 million for Q4 2025, down 30.86% quarter-over-quarter from $2.1 million in Q3 2025.

Alumis (ALMS) Receivables (2025) Analysis & Trends

Alumis (ALMS) has reported Receivables for 1 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
Receivables slipped to $1.4 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
Across five years, Receivables topped out at $5.0 million in Q2 2025 and bottomed at $1.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Alumis	3.25 Bn	2.75 Bn	-	-

Download Data